Patents by Inventor Todd Webster

Todd Webster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mirdametinib treatment
    Patent number: 12324791
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: June 10, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
  • Mirdametinib treatment
    Patent number: 12257215
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: March 25, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
  • Mirdametinib treatment
    Patent number: 12220390
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: February 11, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
  • TREATMENTS WITH NIROGACESTAT
    Publication number: 20250025446
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Application
    Filed: October 7, 2024
    Publication date: January 23, 2025
    Inventors: Allison LIM, Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin PATTERSON
  • Treatments with nirogacestat
    Patent number: 12186305
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: January 16, 2024
    Date of Patent: January 7, 2025
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Treatments with nirogacestat
    Patent number: 12138246
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: April 2, 2024
    Date of Patent: November 12, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT
    Publication number: 20240316007
    Abstract: The present disclosure relates to compositions and methods of treatment comprising nirogacestat or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 6, 2024
    Publication date: September 26, 2024
    Inventors: Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin PATTERSON
  • MIRDAMETINIB TREATMENT
    Publication number: 20240307330
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER
  • MIRDAMETINIB TREATMENT
    Publication number: 20240307329
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER
  • MIRDAMETINIB TREATMENT
    Publication number: 20240307328
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUCO-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER
  • TREATMENTS WITH NIROGACESTAT
    Publication number: 20240245648
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Application
    Filed: April 2, 2024
    Publication date: July 25, 2024
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Treatments with nirogacestat
    Patent number: 12036207
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: December 18, 2023
    Date of Patent: July 16, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • MIRDAMETINIB TREATMENT
    Publication number: 20240226037
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.
    Type: Application
    Filed: March 19, 2024
    Publication date: July 11, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER
  • MIRDAMETINIB TREATMENT
    Publication number: 20240216305
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.
    Type: Application
    Filed: March 19, 2024
    Publication date: July 4, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER
  • MIRDAMETINIB TREATMENT
    Publication number: 20240216306
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/ml, or (iii) both.
    Type: Application
    Filed: March 19, 2024
    Publication date: July 4, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER
  • Treatments with nirogacestat
    Patent number: 12011434
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: June 18, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Treatments with nirogacestat
    Patent number: 12011435
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: January 16, 2024
    Date of Patent: June 18, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • TREATMENTS WITH NIROGACESTAT
    Publication number: 20240189282
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Application
    Filed: January 16, 2024
    Publication date: June 13, 2024
    Inventors: Allison LIM, Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin PATTERSON
  • IMPROVED TREATMENT OF OVARIAN CANCER WITH NIROGACESTAT
    Publication number: 20240180874
    Abstract: The present disclosure relates to improved methods of treating ovarian cancer with nirogacestat.
    Type: Application
    Filed: February 13, 2024
    Publication date: June 6, 2024
    Inventors: Allison LIM, Shinta CHENG, Todd Webster SHEARER, Rex WILLIAMS, Kristin PATTERSON
  • MIRDAMETINIB TREATMENT
    Publication number: 20240173274
    Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.
    Type: Application
    Filed: November 22, 2023
    Publication date: May 30, 2024
    Inventors: Uchenna H. ILOEJE, Abraham J. LANGSETH, Todd Webster SHEARER